Drug interactions between daunorubicin and Herceptin
Results for the following 2 drugs: |
|
|---|---|
| daunorubicin | |
| Herceptin (trastuzumab) | |
Interactions between your selected drugs
daunorubicin ⇔ trastuzumab
Applies to: daunorubicin and Herceptin (trastuzumab)
GENERALLY AVOID: The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline class are individually cardiotoxic and may have additive effects during coadministration. Since trastuzumab has an estimated half-life of 25 days, it may persist in the circulation for up to 22 weeks after stopping treatment. Thus, the use of anthracyclines after stopping trastuzumab may also carry a higher risk of cardiac toxicity.
MANAGEMENT: Trastuzumab and anthracyclines should not be used concurrently in combination except in a well-controlled clinical trial setting with cardiac monitoring. The use of anthracycline-based therapy after stopping trastuzumab should be avoided, if possible, for at least 18 to 22 weeks. If anthracyclines must be used sooner, the patient's cardiac function should be closely monitored.
See also...
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
